Pharma: Other News To Note
Monday, April 9, 2012
Astellas Pharma Inc., of Tokyo, said the FDA's Reproductive Health Drugs Advisory Committee voted 7 to 4, with one abstention, that the overall risk/benefit assessment supported approval of mirabegron (YM178) in overactive bladder. The FDA is not bound to follow the recommendation of advisory panels, but the agency generally does so. Mirabegron's PDUFA date is June 29.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.